ASHLEY BAGGOTT: Open Payments
NPI 1053856443 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,155 in 62 payments from 13 companies in 2025. Trend: 2023 $690 · 2024 $692 · 2025 $1,155
Food & beverage: $1,155
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $387 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $181 |
| Aimmune Therapeutics, Inc. | 6 | $101 |
| Janssen Biotech, Inc. | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 5 | $91 |
| PFIZER INC. | 5 | $85 |
| GENZYME CORPORATION | 2 | $45 |
| Celltrion USA Inc. | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 3 | $35 |
| Ardelyx, Inc. | 2 | $31 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, TREMFYA, MAVYRET, VOWST, XELJANZ, LINZESS.
Industry payments across WA — which companies pay providers there.
